Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
Urologic Oncology|March 10, 2015
Locoregional symptoms in patients with de novo metastatic prostate cancer: Morbidity, management, and disease outcomeAnna Patrikidou, Laurent Brureau, Julien Casenave, et al.
Clinical and Translational Radiation Oncology|August 11, 2018
Helping patients make informed decisions. Two-year evaluation of the Gustave Roussy prostate cancer multidisciplinary clinicAnna Patrikidou, Pierre Maroun, Jean-Jacques Patard, et al.
Annals of Palliative Medicine|April 9, 2021
Health-related quality of life in patients with advanced colorectal cancer: a predictive nomogram including BMI, sex and ageVincenzo Formica, Antonella Nardecchia, Cristina Morelli, et al.
Drugs|May 5, 2022
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate CancerRonan Flippot, Anna Patrikidou, Mihaela Aldea, et al.
European Urology|April 28, 2026
European Association of Urology Guidelines on Testicular Cancer: Summary of the 2026 GuidelinesAnna Patrikidou, Walter Cazzaniga, Christoph Oing, et al.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2015
Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma GroupAnna Patrikidou, Julien Domont, Sylvie Chabaud, et al.
European Urology|May 14, 2023
European Association of Urology Guidelines on Testicular Cancer: 2023 UpdateAnna Patrikidou, Walter Cazzaniga, Daniel Berney, et al.
Cancers|February 25, 2023
Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract CarcinomaPauline Parent, Edouard Auclin, Anna Patrikidou, et al.
European Journal of Cancer (Oxford, England : 1990)|October 28, 2023
Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancerClara Helal, Cédric Pobel, Arnaud Bayle, et al.
Journal of Translational Medicine|February 4, 2023
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancerPier Vitale Nuzzo, Filippo Pederzoli, Calogero Saieva, et al.
Pageof 8